Skip to main content
SpringerLink
Log in

The Role of Transient Elastography for Fibrosis Staging in HCV-Related Chronic Liver Disease

  • Chapter
  • First Online:
Elastography of the Liver and Beyond

  • 337 Accesses

Abstract

The introduction of non-invasive fibrosis tests has revolutionized clinical hepatology and has allowed risk stratification at a much larger scale ever accomplished with liver biopsy. Most non-invasive tests have been developed and calibrated in patients with chronic hepatitis C (CHC), in the era before the direct-acting antivirals. In this chapter, we review the use of elastography in staging of fibrosis in patients with CHC both untreated and post-sustained virological response (SVR). We include data on FibroScan and more recent techniques, such as ARFI and shear wave. We also present data on the prediction of liver-related complications in HCV using elastography, which is particularly important in the post-SVR phase.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.

    Article  Google Scholar 

  2. Alter MJ, Fabiani FL. Epidemiology of hepatitis C virus infection prevalence and incidence. World J Gastroenterol [Internet]. 2007;13(17):2436–41. Available from: www.wjgnet.comhttp://www.wjgnet.com/1007-9327/13/2436.asp

    Article  Google Scholar 

  3. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–8.

    Article  PubMed  Google Scholar 

  4. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.

    Article  Google Scholar 

  5. Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014;20:11033–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology. 2014;60(3):832–43.

    Article  PubMed  Google Scholar 

  7. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8(10):877–83.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rousselet MC, Michalak S, Dupré F, Croué A, Bedossa P, Saint-André JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41(2):257–64.

    Article  PubMed  Google Scholar 

  9. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–57.

    Article  PubMed  Google Scholar 

  10. Castera L, Yuen Chan HL, Arrese M, Afdhal N, Bedossa P, Friedrich-Rust M, et al. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–64.

    Article  Google Scholar 

  11. Tsochatzis E, Gurusamy K, Ntaoula S, Cholongitas E, Davidson B, Burroughs A, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650–9.

    Article  CAS  PubMed  Google Scholar 

  12. Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess (Rockv). 2015;19(9):1–458.

    Article  Google Scholar 

  13. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53(6):1013–21.

    Article  PubMed  Google Scholar 

  14. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.

    Article  PubMed  Google Scholar 

  15. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2020;55(1):199–208. Available from: http://doi.wiley.com/10.1002/hep.24624

    Article  Google Scholar 

  16. Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut. 2008;57(9):1288–93.

    Article  CAS  PubMed  Google Scholar 

  17. Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, et al. Extrahepatic cholestasis increases liver stiffness (fibroScan) irrespective of fibrosis. Hepatology. 2008;48(5):1718–23.

    Article  PubMed  Google Scholar 

  18. Millonig G, Friedrich S, Adolf S, Fonouni H, Golriz M, Mehrabi A, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010;52(2):206–10.

    Article  PubMed  Google Scholar 

  19. Bardou-Jacquet E, Legros L, Soro D, Latournerie M, Guillygomarc’h A, Le Lan C, et al. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol. 2013;19(4):516–22.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 2009;29(10):1500–6.

    Article  PubMed  Google Scholar 

  21. Wai C. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26. Available from: http://doi.wiley.com/10.1053/jhep.2003.50346

    Article  PubMed  Google Scholar 

  22. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357(9262):1069–75.

    Article  CAS  PubMed  Google Scholar 

  23. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.

    Article  PubMed  Google Scholar 

  24. Castéra L, Sebastiani G, Le Bail B, De Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis. J Hepatol. 2010;52(2):191–8.

    Article  PubMed  Google Scholar 

  25. Majumdar A, Campos S, Gurusamy K, Pinzani M, Tsochatzis EA. Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study. Hepatology. 2020;71(2):627–42.

    Article  PubMed  Google Scholar 

  26. Gerber L, Kasper D, Fitting D, Knop V, Vermehren A, Sprinzl K, et al. Assessment of liver fibrosis with 2-D shear wave elastography in comparison to transient elastography and acoustic radiation force impulse imaging in patients with chronic liver disease. Ultrasound Med Biol. 2015;41(9):2350–9.

    Article  PubMed  Google Scholar 

  27. Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33:1138–47.

    Article  PubMed  Google Scholar 

  28. Roccarina D, Iogna Prat L, Buzzetti E, Guerrero Misas M, Aricó FM, Saffioti F, et al. Establishing reliability criteria for liver ElastPQ shear wave elastography (ElastPQ-SWE): comparison between 10, 5 and 3 measurements. Ultraschall Med. 2021;42:204–13.

    Google Scholar 

  29. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012;56(6):2125–33.

    Article  PubMed  Google Scholar 

  30. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18471441

    Article  PubMed  Google Scholar 

  31. Ichikawa S, Motosugi U, Morisaka H, Sano K, Ichikawa T, Tatsumi A, et al. Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis. Magn Reson Imaging. 2015;33(1):26–30.

    Article  PubMed  Google Scholar 

  32. Bohte AE, De Niet A, Jansen L, Bipat S, Nederveen AJ, Verheij J, et al. Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol. 2014;24(3):638–48.

    Article  PubMed  Google Scholar 

  33. Lefebvre T, Wartelle-Bladou C, Wong P, Sebastiani G, Giard JM, Castel H, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. Eur Radiol. 2019;29(12):6477–88.

    Article  PubMed  Google Scholar 

  34. Pons M, Santos B, Simón-Talero M, Ventura-Cots M, Riveiro-Barciela M, Esteban R, et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Ther Adv Gastroenterol. 2017;10(8):619–29.

    Article  CAS  Google Scholar 

  35. D’Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V, et al. The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59(2):251–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23528378

    Article  PubMed  Google Scholar 

  36. Hézode C, Castéra L, Roudot-Thoraval F, Bouvier-Alias M, Rosa I, Roulot D, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656–63.

    Article  PubMed  CAS  Google Scholar 

  37. Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, et al. Therapy with oral directly acting agents in hepatitis c infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9(2):207–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31024203

    Article  PubMed  Google Scholar 

  38. Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2019;72(3):472–80.

    Article  PubMed  Google Scholar 

  39. Tateishi R, Masuzaki R, Enooku K, Kondo Y, Goto T, Ikeda H, et al. Liver stiffness measurement can predict overall survival in patients with chronic hepatitis C. Hepatol Int. 2012;6:149.

    Google Scholar 

  40. De Franchis R, Abraldes JG, Bajaj J, Berzigotti A, Bosch J, Burroughs AK, et al. Expanding consensus in portal hypertension report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.

    PubMed  Google Scholar 

  41. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “anticipate” study. Hepatology. 2016;64(6):2173–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27639071

    Article  CAS  PubMed  Google Scholar 

  42. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. In: The lancet. Lancet Publishing Group; 2014. p. 1749–61.

    Google Scholar 

  43. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32(Suppl.1):141–56.

    Article  CAS  PubMed  Google Scholar 

  44. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16447289

    Article  CAS  PubMed  Google Scholar 

  45. Garcia-Tsao G. Portal hypertension. Curr Opin Gastroenterol. 2004;20:254–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15703650

    Article  PubMed  Google Scholar 

  46. Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. Exp Rev Gastroenterol Hepatol. 2018;12:155–64.

    Article  CAS  Google Scholar 

  47. Shi KQ, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int. 2013;33(1):62–71.

    Article  PubMed  Google Scholar 

  48. Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol. 2012;56(1):103–8.

    Article  PubMed  Google Scholar 

  49. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45(5):1290–7.

    Article  PubMed  Google Scholar 

  50. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol. 2012;47(5):561–8.

    Article  CAS  PubMed  Google Scholar 

  51. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Elène Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the ‘anticipate’ study. Hepatology. 2016;64(6):2173–84.

    Article  CAS  PubMed  Google Scholar 

  52. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–35. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/hep.28906

    Article  PubMed  Google Scholar 

  53. Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008;27(12):1261–8.

    Article  CAS  PubMed  Google Scholar 

  54. Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther. 2008;28(9):1102–10.

    Article  CAS  PubMed  Google Scholar 

  55. Kazemi F, Kettaneh A, N’kontchou G, Pinto E, Ganne-Carrie N, Trinchet JC, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45(2):230–5.

    Article  PubMed  Google Scholar 

  56. Nguyen-Khac E, Saint-Leger P, Tramier B, Coevoet H, Capron D, Dupas JL. Noninvasive diagnosis of large esophageal varices by fibroscan: strong influence of the cirrhosis etiology. Alcohol Clin Exp Res. 2010;34(7):1146–53.

    CAS  PubMed  Google Scholar 

  57. Pritchett S, Cardenas A, Manning D, Curry M, Afdhal NH. The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific. J Viral Hepat. 2011;18(4):e75–80.

    Article  CAS  PubMed  Google Scholar 

  58. Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56(3):696–703.

    Article  PubMed  Google Scholar 

  59. Maurice JB, Brodkin E, Arnold F, Navaratnam A, Paine H, Khawar S, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol. 2016;65(5):899–905.

    Article  PubMed  Google Scholar 

  60. Jangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia-Tsao G. Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int. 2017;37(8):1177–83.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Llop E, Lopez M, de la Revilla J, Fernandez N, Trapero M, Hernandez M, et al. Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease. J Gastroenterol Hepatol. 2017;32(11):1867–72.

    Article  PubMed  Google Scholar 

  62. Sousa M, Fernandes S, Proença L, Silva AP, Leite S, Silva J, et al. The Baveno VI criteria for predicting esophageal varices: validation in real life practice. Rev Esp Enferm Dig. 2017;109(10):704–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28776387

    PubMed  Google Scholar 

  63. Augustin S, Onica Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017;66:1980–8.

    Article  PubMed  Google Scholar 

  64. Colecchia A, Montrone L, Scaioli E, Bacchireggiani ML, Colli A, Casazza G, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology. 2012;143(3):646–54.

    Article  PubMed  Google Scholar 

  65. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transplant. 2010;16(6):748–59.

    Google Scholar 

  66. Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology. 2019;156:2149–57.

    Article  PubMed  Google Scholar 

  67. Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol. 2017:1–19.

    Google Scholar 

  68. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204–12.

    Article  CAS  PubMed  Google Scholar 

  69. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33.

    Article  CAS  PubMed  Google Scholar 

  70. Degasperi E, D’Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 2019;17(6):1183–1191.e7.

    Article  CAS  PubMed  Google Scholar 

  71. Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, Buonfiglioli F, et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis. 2018;50(6):573–9.

    Article  PubMed  Google Scholar 

  72. Vergniol J, Foucher J, Terrebonne E, Bernard P, Le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1970–1979.e3.

    Article  PubMed  Google Scholar 

  73. Vergniol J, Boursier J, Coutzac C, Bertrais S, Foucher J, Angel C, et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology. 2014;60(1):65–76.

    Article  PubMed  Google Scholar 

  74. Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, et al. Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: a systematic review and meta-analysis. J Viral Hepat. 2018;25(5):502–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK

    Marta Cilla & Emmanuel A. Tsochatzis

  2. UCL Institute for Liver and Digestive Health, Royal Free Hospital, UCL, London, UK

    Marta Cilla & Emmanuel A. Tsochatzis

Authors
  1. Marta Cilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuel A. Tsochatzis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel A. Tsochatzis .

Editor information

Editors and Affiliations

  1. Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Mirella Fraquelli

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cilla, M., Tsochatzis, E.A. (2021). The Role of Transient Elastography for Fibrosis Staging in HCV-Related Chronic Liver Disease. In: Fraquelli, M. (eds) Elastography of the Liver and Beyond. Springer, Cham. https://doi.org/10.1007/978-3-030-74132-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74132-7_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74131-0

  • Online ISBN: 978-3-030-74132-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation